Last reviewed · How we verify
WX-0593
At a glance
| Generic name | WX-0593 |
|---|---|
| Also known as | FL-006 |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
- Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer (PHASE2)
- Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients (PHASE2)
- Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (PHASE3)
- Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (PHASE2)
- Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male Volunteers (PHASE1)
- WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC (PHASE2)
- A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WX-0593 CI brief — competitive landscape report
- WX-0593 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI